<DOC>
	<DOCNO>NCT01691924</DOCNO>
	<brief_summary>No clinical trial PBF-509 human perform date . Only preclinical study do assess pharmacology pharmacokinetics , safety toxicological profile PBF-509 . An initial test PBF-509 human plan , start first-into-man clinical trial single oral , dose-escalating , placebo-controlled design implement .</brief_summary>
	<brief_title>Study To Assess Safety Tolerability PBF-509 Male Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>Each subject must meet follow inclusion criterion prestudy screen visit ( within 4 week prior dose ) order participate study . Healthy male subject , 1845 year age . Clinically acceptable blood pressure pulse rate supine stand position . Blood pressure pulse measure minimum 3 minute rest . Body weight within normal range ( Quetelet 's index 19 26 ) express weight ( kg ) / height ( m2 ) .. Nonsmokers ( refrain tobacco usage , include smokeless tobacco , nicotine patch , etc. , 6 month prior administration study medication ) . Able understand nature study comply requirement . Free acceptance participate study obtains sign informed consent form approve Ethics Committee Hospital ( CEIC ) . History serious adverse reaction hypersensitivity drug . Presence history allergy require acute chronic treatment ( except seasonal allergic rhinitis ) . Background clinical evidence chronic disease . Acute illness two week drug administration . Having undergone major surgery previous 6 month . History alcohol drug abuse last 5 year . Abnormal physical finding clinical significance screen examination baseline would interfere objective study . Need prescription medication within 14 day prior administration drug non prescription medication herbal medicine within 7 day prior administration drug . Participation clinical trial previous 90 day investigational drug commercially available drug test . Not donate blood 3 month period inclusion study . Existence surgical medical condition might interfere absorption , distribution , metabolism excretion drug , i.e . impaired renal hepatic function , diabetes mellitus , cardiovascular abnormality , chronic symptom pronounce constipation diarrhea condition associate total partial obstruction urinary tract . 12 lead ECG obtain screen PR &gt; 220 msec , QRS &gt; 120 msec QTc &gt; 440 msec , bradycardia ( &lt; 50 bpm ) clinically significant minor ST wave change abnormal change screen ECG . Symptoms significant somatic mental illness four week period precede drug administration . History hepatitis B / C / positive serology result indicate presence hepatitis B / C. Positive result HIV serology . Clinically significant abnormal laboratory value ( determine Principal Investigator ) screen evaluation . Positive result drug screen day start treatment period . Known hypersensitivity study drug composition galenical form History psychiatric disease epileptic seizure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Adenosine A2a receptor antagonist</keyword>
	<keyword>adenosine receptor modulator</keyword>
	<keyword>Cancer</keyword>
</DOC>